Valeria Forestieri
A5057558150- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Risks and Factors
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Metabolism, Diabetes, and Cancer
- BRCA gene mutations in cancer
- Prostate Cancer Treatment and Research
- Endometrial and Cervical Cancer Treatments
- Cancer, Lipids, and Metabolism
- Ovarian cancer diagnosis and treatment
- Lung Cancer Treatments and Mutations
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Multiple and Secondary Primary Cancers
- Brain Metastases and Treatment
- Neutropenia and Cancer Infections
- Bone health and treatments
- Reproductive System and Pregnancy
- Intraperitoneal and Appendiceal Malignancies
- COVID-19 and healthcare impacts
University of Naples Federico II
2015-2025
Federico II University Hospital
2012-2022
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2013-2019
Baylor College of Medicine
2019
Clinica Mediterranea
2013
Abstract Purpose Obesity and insulin resistance have been associated with poor prognosis in breast cancer (BC). The present prospective study aimed to investigate the impact of metabolic syndrome (MetS) its components on early BC (eBC) patients’ outcome. Methods MetS was defined by presence 3 5 following components: waist circumference > 88 cm, blood pressure ≥ 130/≥ 85 mmHg, serum levels triglycerides 150 mg/dL, high density lipoprotein < 50 mg/dL fasting glucose 110 mg/dL. Seven...
Weight gain and metabolic changes have been related to survival of early breast cancer patients (EBC). ''However, factors influencing metabolism post-diagnosis are not fully understood. We measured anthropometric [body mass index (BMI), body weight, waist hip circumferences, waist-to-hip ratio] (levels insulin, glucose, H1Ac, total, HDL, LDL cholesterol, triglycerides, the homeostasis model assessment score [HOMA]) parameters in 433 pre- post-menopausal women with EBC at diagnosis 3, 6, 9,...
Male breast cancer (MBC) is rare. Given the paucity of randomized trials, treatment generally extrapolated from female guidelines.This a retrospective analysis all male patients presenting with MBC at Department Oncology University Federico II Naples between January 1989 and 2014. We recorded following data: baseline characteristics (age, height, weight, body mass index, risk factors, family history), tumor (side affected, stage, histotype, hormonal HER2 status, Ki-67 expression), (type...
Approximately 5–10% of breast cancers are hereditary and their biology prognosis appear to differ from those sporadic cancers. In this study we compared the biological features clinical characteristics non metastatic cancer in patients with BRCA mutations versus a family history suggesting but without (BRCA wild type) disease, correlated these findings outcome. We retrieved data 33 BRCA-positive, 66 BRCA-wild type 1826 contained single institution database between 1980 2012. Specifically,...
// Giuseppe Buono 1, * , Anna Crispo 2, Mario Giuliano 3 Carmine De Angelis 1 Francesco Schettini Valeria Forestieri Rossella Lauria Matilde Pensabene Michelino Laurentiis 4 Livia Silvia Adriana Augustin 5 Alfonso Amore Massimiliano D'Aiuto Raffaele Tortoriello Antonello Accurso 6 Ernesta Cavalcanti 2 Gerardo Botti Maurizio Montella Sabino Placido and Grazia Arpino Department of Clinical Medicine Surgery, Oncology Division, University Naples Federico II, Naples, Italy Unit Epidemiology,...
AbstractAim. This is a phase I study investigating the toxicity and potential efficacy of thalidomide oral cyclophosphamide in patients with hormone refractory prostate cancer (HRPC), previously treated docetaxel-based regimens.Methods. Two dose levels (100 200 mg every day) were studied. Patients accrued to each level cohorts 3 starting from 1 mg). Thalidomide was started on day at assigned continued for 4 consecutive weeks; (50 given weeks (1 cycle) same initiating thalidomide. Toxicity...
Immunosuppression induced by anticancer therapy in a COVID-19-positive asymptomatic patient with cancer may have devastating effect and, eventually, be lethal. To identify cases among patients receiving active treatment, the Federico II University Hospital Naples performs rapid serological tests addition to hospital standard clinical triage for COVID-19 infection.From 6 17 April 2020, all candidates chemotherapy, radiotherapy or target/immunotherapy, if negative at on day scheduled received...
•Bevacizumab + chemotherapy improved progression-free survival in HER2-negative metastatic breast cancer (MBC) patients.•Eribulin monotherapy overall patients with anthracycline- and taxane-pretreated MBC.•The GIM11-BERGI trial assessed the efficacy safety of eribulin bevacizumab as second-line treatment for HER2-MBC.•Eribulin showed to be a safe active after progression first-line paclitaxel bevacizumab. BackgroundWe evaluated nontaxane microtubule dynamics inhibitor plus humanized...
The partner and localizer of BRCA2 ( PALB2 ) is a major binding that participates in homologous recombination repair response to DNA double-strand breaks. Germline alterations the gene have recently been associated with high risk developing breast cancer. We investigated 37-year-old Caucasian woman cancer family history using targeted next generation sequencing. A novel heterozygous deletion involving exons 5 6 was found gene, resulted production truncated protein. These findings expand...
We describe the case of a woman who has been undergoing treatment for HER2-positive metastatic breast cancer since 2002. She presented liver metastasis at diagnosis in February Combination therapy with docetaxel and trastuzumab was administered as first-line treatment, complete response hepatic lesion partial primary site were achieved. After 6 cycles therapy, patient underwent surgical excision then received alone until progression, which occurred March 2010 development right chest wall...